Delivery Order SPE2DB22D2007-SPE2DB25FJ4AF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector vials valued at $3,609.99 with completion targeted for August 19, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed price terms and is performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $1,629.66 delivery order to AmerisourceBergen Drug Corp for XYOSTED 50 mg/0.5 mL auto-injector supplies, with a completion date of July 31, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place...
- The Defense Logistics Agency awarded a delivery order valued at $1,524.90 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector supplies on July 18, 2025, with completion targeted for July 21, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award based on capability. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical delivery order. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- The Defense Logistics Agency awarded a delivery order valued at $1,150.15 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector supplies. The contract, which is non-set-aside and competitively awarded, was issued on August 1, 2025, with an ultimate completion date of August 4, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order operates under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,188.98 on July 22, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 23, 2025, and performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,358.05 to AmerisourceBergen Drug Corp for XYOSTED 50 MG/0.5 ML auto-injectors (0.5 ML) on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order was not set-aside and competitively awarded. The product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $1,629.66 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, represents a small-value pharmaceutical procurement fulfilled through performance in Conshohocken, Pennsylvania. The award was made competitively with no set-aside designation and is classified as a child contract under a larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $1,358.05 by the Defense Logistics Agency (DLA) for XYOSTED 75 MG/0.5 ML auto-injector pharmaceutical products. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by July 23, 2025. The award was issued on July 22, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4AFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of XYOSTED 75 mg/0.5 ml auto-injector medication with a ceiling value of $1,009.73. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 19, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through the DLA Medical Supply Chain. The company's comprehensive IDC vehicle enables delivery of a broad portfolio of pharmaceutical products and medical supplies—including specialty medications, brand-name and generic drugs, vaccines, syringes, and medical devices—to support military healthcare programs worldwide. All of AmerisourceBergen's reviewed contract awards with the DLA have been competitively awarded through open competition, demonstrating the company's capability to meet federal procurement standards across a wide spectrum of therapeutic domains and customer bases including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 8/18/25 |